Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Convertible Debt of $310.3 million for Q1 2026, up 0.56% year-over-year from $308.5 million in Q1 2025, and little changed quarter-over-quarter from $309.8 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $310.3 million for Q1 2026.
- In Q1 2026, Convertible Debt rose 0.56% year-over-year to $310.3 million; the TTM figure through Mar 2026 stood at $310.3 million (up 0.56% YoY), while the FY2025 annual figure was $309.8 million, up 0.56% from the prior year.
- Convertible Debt for Q1 2026 stood at $310.3 million, roughly flat from $309.8 million in the prior quarter.
- The five-year high for Convertible Debt was $310.3 million in Q1 2026, with the low at $305.6 million in Q2 2023.
- The 4-year median for Convertible Debt is $307.9 million (2024), against an average of $307.9 million.
- The sharpest annual moves came in 2024 and 2026: Convertible Debt rose 0.53% in 2024, then climbed 0.56% in 2026.
- Mirum Pharmaceuticals' Convertible Debt stood at $306.4 million in 2023, then rose by 0.54% to $308.1 million in 2024, then advanced by 0.56% to $309.8 million in 2025, then climbed by 0.15% to $310.3 million in 2026.
- Business Quant data shows MIRM's Convertible Debt at $310.3 million in Q1 2026, $309.8 million in Q4 2025, and $309.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 750.08 Mn |
| Mar 31, 2026 | 310.25 Mn |
| Dec 31, 2025 | 309.80 Mn |
| Sep 30, 2025 | 309.37 Mn |
| Jun 30, 2025 | 308.93 Mn |
| Mar 31, 2025 | 308.51 Mn |
| Dec 31, 2024 | 308.08 Mn |
| Sep 30, 2024 | 307.67 Mn |
| Jun 30, 2024 | 307.24 Mn |
| Mar 31, 2024 | 306.84 Mn |
| Dec 31, 2023 | 306.42 Mn |
| Sep 30, 2023 | 306.02 Mn |
| Jun 30, 2023 | 305.61 Mn |